{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:26:31Z","timestamp":1788989191964,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sinew Pharma Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05686-7","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:03:00Z","timestamp":1728914580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct03868566","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hsin-Tien","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lueng","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hsien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Weim","family":"Hsiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Min","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Huei","family":"Hsiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-En","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9055-0270","authenticated-orcid":false,"given":"Oliver Yoa-Pu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"5686_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3.","journal-title":"Lancet"},{"key":"5686_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333. https:\/\/doi.org\/10.1002\/hep.29466.","journal-title":"Hepatology"},{"key":"5686_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"key":"5686_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2741\/4892","volume":"26","author":"S Raza","year":"2021","unstructured":"Raza S, Rajak S, Upadhyay A, Tewari A, Anthony SR. Current treatment paradigms and emerging therapies for NAFLD\/NASH. Front Biosci. 2021;26:206\u201337. https:\/\/doi.org\/10.2741\/4892.","journal-title":"Front Biosci"},{"key":"5686_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100051","volume":"2","author":"KV Sanjay","year":"2021","unstructured":"Sanjay KV, Vishwakarma S, Zope BR, Mane VS, Mohire S, Dhakshinamoorthy S. ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. Curr Res Pharmacol Drug Discov. 2021;2: 100051. https:\/\/doi.org\/10.1016\/j.crphar.2021.100051.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"5686_CR6","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","volume":"155","author":"R Loomba","year":"2018","unstructured":"Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155:1463-73.e6. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.027.","journal-title":"Gastroenterology"},{"key":"5686_CR7","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","volume":"72","author":"V Ratziu","year":"2020","unstructured":"Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020;72:892\u2013905. https:\/\/doi.org\/10.1002\/hep.31108.","journal-title":"Hepatology"},{"key":"5686_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.027.","journal-title":"J Hepatol"},{"key":"5686_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1\u2013F3 fibrosis. J Hepatol. 2020;72:816\u201327. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.024.","journal-title":"J Hepatol"},{"key":"5686_CR10","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.3390\/ijms23158805","volume":"23","author":"RZ Carpi","year":"2022","unstructured":"Carpi RZ, Barbalho SM, Sloan KP, Laurindo LF, Gonzaga HF, Grippa PC, et al. The effects of probiotics, prebiotics and Synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review. Int J Mol Sci. 2022;23:8805. https:\/\/doi.org\/10.3390\/ijms23158805.","journal-title":"Int J Mol Sci"},{"key":"5686_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.31236","volume":"72","author":"W Chen","year":"2020","unstructured":"Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis. Hepatology. 2020;72:729\u201341. https:\/\/doi.org\/10.1002\/hep.31236.","journal-title":"Hepatology"},{"key":"5686_CR12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: Data from the simtuzumab trials. Hepatology. 2019;70:1913\u201327. https:\/\/doi.org\/10.1002\/hep.30664.","journal-title":"Hepatology"},{"key":"5686_CR13","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, et al. Effects of Belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158:1334-1345.e5. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.296.","journal-title":"Gastroenterology"},{"key":"5686_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012.","journal-title":"Metabolism"},{"key":"5686_CR15","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.3748\/wjg.v28.i35.5129","volume":"28","author":"J Suri","year":"2022","unstructured":"Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol. 2022;28:5129\u201340. https:\/\/doi.org\/10.3748\/wjg.v28.i35.5129.","journal-title":"World J Gastroenterol"},{"key":"5686_CR16","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","volume":"78","author":"V Ratziu","year":"2023","unstructured":"Ratziu V, Charlton M. Rational combination therapy for NASH: insights from clinical trials and error. J Hepatol. 2023;78:1073\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.025.","journal-title":"J Hepatol"},{"key":"5686_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116\u201341. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.025.","journal-title":"Free Radic Biol Med"},{"key":"5686_CR18","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313\u201327. https:\/\/doi.org\/10.1007\/s00018-018-2860-6.","journal-title":"Cell Mol Life Sci"},{"key":"5686_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111326","volume":"137","author":"K Wang","year":"2021","unstructured":"Wang K, Tan W, Liu X, Deng L, Huang L, Wang X, et al. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. Biomed Pharmacother. 2021;137: 111326. https:\/\/doi.org\/10.1016\/j.biopha.2021.111326.","journal-title":"Biomed Pharmacother"},{"key":"5686_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158221","author":"R Harjum\u00e4ki","year":"2021","unstructured":"Harjum\u00e4ki R, Pridgeon CS, Ingelman-Sundberg M. CYP2E1 in alcoholic and non-alcoholic liver injury roles of ROS, reactive intermediates and lipid overload. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22158221.","journal-title":"Int J Mol Sci"},{"key":"5686_CR21","doi-asserted-by":"publisher","first-page":"42566","DOI":"10.1038\/srep42566","volume":"7","author":"MA Abdelmegeed","year":"2017","unstructured":"Abdelmegeed MA, Choi Y, Godlewski G, Ha SK, Banerjee A, Jang S, et al. Corrigendum: cytochrome P450\u20132E1 promotes fast food-mediated hepatic fibrosis. Sci Rep. 2017;7:42566. https:\/\/doi.org\/10.1038\/srep42566.","journal-title":"Sci Rep"},{"key":"5686_CR22","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2012.05.019","volume":"57","author":"MA Abdelmegeed","year":"2012","unstructured":"Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol. 2012;57:860\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2012.05.019.","journal-title":"J Hepatol"},{"key":"5686_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1053\/jhep.2003.50095","volume":"37","author":"N Chalasani","year":"2003","unstructured":"Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003;37:544\u201350. https:\/\/doi.org\/10.1053\/jhep.2003.50095.","journal-title":"Hepatology"},{"key":"5686_CR24","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1440-1746.2009.06196.x","volume":"25","author":"E Kathirvel","year":"2010","unstructured":"Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol. 2010;25:1136\u201343. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.06196.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"5686_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/hep.510270121","volume":"27","author":"MD Weltman","year":"1998","unstructured":"Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998;27:128\u201333. https:\/\/doi.org\/10.1002\/hep.510270121.","journal-title":"Hepatology"},{"key":"5686_CR26","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.biopha.2017.11.043","volume":"97","author":"T Jian","year":"2018","unstructured":"Jian T, Wu Y, Ding X, Lv H, Ma L, Zuo Y, et al. A novel sesquiterpene glycoside from Loquat leaf alleviates oleic acid-induced steatosis and oxidative stress in HepG2 cells. Biomed Pharmacother. 2018;97:1125\u201330. https:\/\/doi.org\/10.1016\/j.biopha.2017.11.043.","journal-title":"Biomed Pharmacother"},{"key":"5686_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/j.1552-4604.1998.tb04381.x","volume":"38","author":"RF Frye","year":"1998","unstructured":"Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol. 1998;38:82\u20139. https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04381.x.","journal-title":"J Clin Pharmacol"},{"key":"5686_CR28","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.4254\/wjh.v13.i11.1584","volume":"13","author":"P Pal","year":"2021","unstructured":"Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol. 2021;13:1584\u2013610. https:\/\/doi.org\/10.4254\/wjh.v13.i11.1584.","journal-title":"World J Hepatol"},{"key":"5686_CR29","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.2147\/DDDT.S315724","volume":"15","author":"JM Fraile","year":"2021","unstructured":"Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-alcoholic steatohepatitis (NASH)\u2014a review of a crowded clinical landscape, driven by a complex disease. Drug Des Dev Ther. 2021;15:3997\u20134009. https:\/\/doi.org\/10.2147\/DDDT.S315724.","journal-title":"Drug Des Dev Ther"},{"key":"5686_CR30","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","volume":"69","author":"JF Dufour","year":"2020","unstructured":"Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69:1877\u201384. https:\/\/doi.org\/10.1136\/gutjnl-2019-319104.","journal-title":"Gut"},{"key":"5686_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022;77:607\u201318. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.003.","journal-title":"J Hepatol"},{"key":"5686_CR32","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130:1453\u201360. https:\/\/doi.org\/10.1172\/JCI134165.","journal-title":"J Clin Invest"},{"key":"5686_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","volume":"63","author":"F Ameer","year":"2014","unstructured":"Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism. 2014;63:895\u2013902. https:\/\/doi.org\/10.1016\/j.metabol.2014.04.003.","journal-title":"Metabolism"},{"key":"5686_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","volume":"91","author":"FW Sanders","year":"2016","unstructured":"Sanders FW, Griffin JL. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016;91:452\u201368. https:\/\/doi.org\/10.1111\/brv.12178.","journal-title":"Biol Rev Camb Philos Soc"},{"key":"5686_CR35","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039.","journal-title":"J Hepatol"},{"key":"5686_CR36","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.apsb.2022.02.004","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Yan T, Wang T, Liu X, Hamada K, Sun D, et al. Crosstalk between CYP2E1 and PPAR\u03b1 substrates and agonists modulate adipose browning and obesity. Acta Pharm Sin B. 2022;12:2224\u201338. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.004.","journal-title":"Acta Pharm Sin B"},{"key":"5686_CR37","doi-asserted-by":"publisher","first-page":"E1118","DOI":"10.1152\/ajpendo.00585.2012","volume":"304","author":"M Konstandi","year":"2013","unstructured":"Konstandi M, Cheng J, Gonzalez FJ. Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver. Am J Physiol Endocrinol Metab. 2013;304:E1118\u201328. https:\/\/doi.org\/10.1152\/ajpendo.00585.2012.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"5686_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fimmu.2020.01169","volume":"11","author":"H Li","year":"2020","unstructured":"Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, et al. Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol. 2020;11:1169. https:\/\/doi.org\/10.3389\/fimmu.2020.01169.","journal-title":"Front Immunol"},{"key":"5686_CR39","doi-asserted-by":"publisher","first-page":"G95","DOI":"10.1152\/ajpgi.00383.2004","volume":"289","author":"Q Cao","year":"2005","unstructured":"Cao Q, Mak KM, Lieber CS. Cytochrome P4502E1 primes macrophages to increase TNF-alpha production in response to lipopolysaccharide. Am J Physiol Gastrointest Liver Physiol. 2005;289:G95\u2013107. https:\/\/doi.org\/10.1152\/ajpgi.00383.2004.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"5686_CR40","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.12063","volume":"43","author":"Q Ye","year":"2013","unstructured":"Ye Q, Wang X, Wang Q, Xia M, Zhu Y, Lian F, et al. Cytochrome P4502E1 inhibitor, chlormethiazole, decreases lipopolysaccharide-induced inflammation in rat Kupffer cells with ethanol treatment. Hepatol Res. 2013;43:1115\u201323. https:\/\/doi.org\/10.1111\/hepr.12063.","journal-title":"Hepatol Res"},{"key":"5686_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967410","volume":"13","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhang H, Yao Y, Zhang X, Guan Y, Zheng F. CD4+ T cell activation and inflammation in NASH-related fibrosis. Front Immunol. 2022;13: 967410. https:\/\/doi.org\/10.3389\/fimmu.2022.967410.","journal-title":"Front Immunol"},{"key":"5686_CR42","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/hep.32336","volume":"75","author":"P Ramadori","year":"2022","unstructured":"Ramadori P, Kam S, Heikenwalder M. T cells: friends and foes in NASH pathogenesis and hepatocarcinogenesis. Hepatology. 2022;75:1038\u201349. https:\/\/doi.org\/10.1002\/hep.32336.","journal-title":"Hepatology"},{"key":"5686_CR43","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","volume":"592","author":"M Dudek","year":"2021","unstructured":"Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature. 2021;592:444\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03233-8.","journal-title":"Nature"},{"key":"5686_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153831","volume":"8","author":"A Woestemeier","year":"2023","unstructured":"Woestemeier A, Scognamiglio P, Zhao Y, Wagner J, Muscate F, Casar C, et al. Multicytokine-producing CD4+ T cells characterize the livers of patients with NASH. JCI Insight. 2023;8: e153831. https:\/\/doi.org\/10.1172\/jci.insight.153831.","journal-title":"JCI Insight"},{"key":"5686_CR45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s42255-019-0093-0","volume":"1","author":"JT Haas","year":"2019","unstructured":"Haas JT, Vonghia L, Mogilenko DA, Verrijken A, Molendi-Coste O, Fleury S, et al. Author correction: transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. Nat Metab. 2019;1:744. https:\/\/doi.org\/10.1038\/s42255-019-0093-0.","journal-title":"Nat Metab"},{"key":"5686_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.1501175","volume":"196","author":"M Rau","year":"2016","unstructured":"Rau M, Schilling AK, Meertens J, Hering I, Weiss J, Jurowich C, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol. 2016;196:97\u2013105. https:\/\/doi.org\/10.4049\/jimmunol.1501175.","journal-title":"J Immunol"},{"key":"5686_CR47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41586-023-05801-6","volume":"615","author":"F Zani","year":"2023","unstructured":"Zani F, Blagih J, Gruber T, Buck MD, Jones N, Hennequart M, et al. The dietary sweetener sucralose is a negative modulator of T cell-mediated responses. Nature. 2023;615:705\u201311. https:\/\/doi.org\/10.1038\/s41586-023-05801-6.","journal-title":"Nature"},{"key":"5686_CR48","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/cells10040768","volume":"10","author":"HJ Jeon","year":"2021","unstructured":"Jeon HJ, Choi DK, Choi J, Lee S, Lee H, Yu JH, et al. D-mannitol induces a brown fat-like phenotype via a \u03b23-adrenergic receptor-dependent mechanism. Cells. 2021;10:768. https:\/\/doi.org\/10.3390\/cells10040768.","journal-title":"Cells"},{"key":"5686_CR49","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","volume":"76","author":"ME Rinella","year":"2022","unstructured":"Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the regenerate study. J Hepatol. 2022;76:536\u201348. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.029.","journal-title":"J Hepatol"},{"key":"5686_CR50","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(19)32517-6.","journal-title":"Lancet"},{"key":"5686_CR51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","volume":"17","author":"M Eslam","year":"2020","unstructured":"Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17:40\u201352. https:\/\/doi.org\/10.1038\/s41575-019-0212-0.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5686_CR52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.12998\/wjcc.v6.i8.167","volume":"6","author":"JZ Wang","year":"2018","unstructured":"Wang JZ, Cao HX, Chen JN, Pan Q. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases. 2018;6:167\u201375. https:\/\/doi.org\/10.12998\/wjcc.v6.i8.167.","journal-title":"World J Clin Cases"},{"key":"5686_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.734847","volume":"8","author":"M Dallio","year":"2021","unstructured":"Dallio M, Masarone M, Romeo M, Tuccillo C, Morisco F, Persico M, et al. PNPLA3, TM6SF2, and MBOAT7 influence on nutraceutical therapy response for non-alcoholic fatty liver disease: a randomized controlled trial. Front Med. 2021;8: 734847. https:\/\/doi.org\/10.3389\/fmed.2021.734847.","journal-title":"Front Med"},{"key":"5686_CR54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","volume":"147","author":"F Marra","year":"2014","unstructured":"Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577-94.e1. https:\/\/doi.org\/10.1053\/j.gastro.2014.06.043.","journal-title":"Gastroenterology"},{"issue":"10","key":"5686_CR55","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","volume":"69","author":"JF Dufour","year":"2020","unstructured":"Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69(10):1877\u201384. https:\/\/doi.org\/10.1136\/gutjnl-2019-319104.","journal-title":"Gut"},{"issue":"2","key":"5686_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1515\/mr-2024-0007","volume":"4","author":"ZSW Chui","year":"2024","unstructured":"Chui ZSW, Xue Y, Xu A. Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease. Med Rev. 2024;4(2):158\u201368. https:\/\/doi.org\/10.1515\/mr-2024-0007.","journal-title":"Med Rev"},{"issue":"7800","key":"5686_CR57","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-020-2101-7","volume":"579","author":"S Zhao","year":"2020","unstructured":"Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 2020;579(7800):586\u201391. https:\/\/doi.org\/10.1038\/s41586-020-2101-7.","journal-title":"Nature"},{"key":"5686_CR58","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1172\/JCI8814","volume":"105","author":"IA Leclercq","year":"2000","unstructured":"Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Investig. 2000;105:1067\u201375. https:\/\/doi.org\/10.1172\/JCI8814.","journal-title":"J Clin Investig"},{"key":"5686_CR59","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41401-022-00874-x","volume":"43","author":"XF Tong","year":"2022","unstructured":"Tong XF, Wang QY, Zhao XY, Sun YM, Wu XN, Yang LL, et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin. 2022;43:1200\u20139. https:\/\/doi.org\/10.1038\/s41401-022-00874-x.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05686-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05686-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05686-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:06:18Z","timestamp":1728914778000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05686-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5686"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05686-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines from the International Conference on Harmonisation, and local applicable regulatory requirements. All procedures were approved by the institutional review boards\/independent ethics committee at the leading site (Tri-Service General Hospital; IRB No.: 1-106-05-062). All patients provided written informed consent prior to screening. All animal husbandry, care, euthanasia, and use procedures followed the guidelines established by the Institutional Animal Care and Use Committees of the National Defense Medical Center (approval number: IACUC-15-309).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"936"}}